This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthcare Investors Suffering Losses While Drug-Pricing War Rages

04/08/14 - 11:23 AM EDT

The latest salvo was lobbed Tuesday by pharmacy benefits manager Express Scripts against Gilead Sciences and its $1,000-per-day hepatitis C pill Sovaldi. Express Scripts says the U.S. healthcare system can't afford Sovaldi so it wants to form a coalition of private employers, insurance companies and the government focused on fair drug pricing. But first, Express wants Gilead to cut the price of Sovaldi or be frozen out when competing hepatitis C therapies are approved later this year and next, according to a Bloomberg report.

READ FULL POST

Alkermes Will Seek U.S. Approval for Once-Monthly Schizophrenia Treatment

04/08/14 - 09:11 AM EDT

If approved next year, Alkermes' aripiprazole lauroxil will compete against several other long-acting antipsychotics, including a similar once-monthly injectable aripiprazole approved last year and sold by Otuska and Lundbeck. But the schizophrenia treatment market (oral and injectable drugs) is big and growing -- more than $11 billion in the U.S. last year and $20 billion-plus worldwide. Oral versions of aripiprazole, sold under the brand name Abilify, generated $6.5 billion in sales last year.

READ FULL POST

Tradable Biotech Stock Events for the Second Quarter

04/03/14 - 09:00 AM EDT

The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.

READ FULL POST

Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study

04/03/14 - 08:30 AM EDT

Northwest Bio is now acknowledging that no agreement with the FDA was ever reached on the progression-free survival (PFS) primary endpoint for the DCVax phase III brain cancer study.

READ FULL POST

Prana Alzheimer's Study Fails

03/31/14 - 06:54 AM EDT

The experimental drug PBT2 failed to reduce beta amyloid plaque in the brain and couldn't improve cognition or function in Alzheimer's patients.

READ FULL POST

Northwest Bio, DCVax and 'Compassionate Use'

03/29/14 - 11:33 AM EDT

Northwest Biotherapeutics takes umbrage at anyone who describes the German Hospital Exemption decision for its brain cancer vaccine DCVax as "compassionate use" -- except when they do it.

READ FULL POST

Poof! Biotech's 2014 Outperformance is Gone

03/28/14 - 04:16 PM EDT

Biotech stocks continue to melt down. I know, broken record, but like a car wreck, it's hard not to look.

READ FULL POST

Northwest Bio CEO Discloses More Problems With DC-Vax Brain Cancer Study

03/27/14 - 04:21 PM EDT

Northwest Biotherapeutics CEO Linda Powers took to a podium at a conference in New York this afternoon and dribbled out some new information about the company's cancer vaccine DC-Vax and the ongoing phase III study in brain cancer. Powers is a skilled dissembler, so her update, while amazingly negative for DC-Vax, was spun positive. It was an award-winning performance.

READ FULL POST

Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM

03/26/14 - 05:14 PM EDT

Novartis' ceritinib is a next-generation ALK inhibitor already under FDA review as a new treatment for lung cancer.

READ FULL POST

Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis

03/26/14 - 11:42 AM EDT

Exelixis shares fall after independent data monitors concluded a closely watched phase III study of cabozantinib in advanced prostate cancer should continue to the final analysis expected later this year.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 17,104.80 -8.74 -0.05%
S&P 500 1,988.72 +5.19 0.26%
NASDAQ 4,477.86 +21.8440 0.49%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs